+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
A

Actively Recruiting

Researchers are evaluating two different strategies for complete revascularization in patients with significant coronary artery disease CAD who are undergoing percutaneous coronary intervention PCI with drug-eluting stents DES. The study compares quantitative coronary angiography QCA-guided anatomic complete revascularization and fractional flow reserve FFR-guided physiologic complete revascularization. This prospective, multicenter, randomized trial includes patients with symptoms or evidence of myocardial ischemia and specific stenotic lesions in major coronary arteries. Participants are randomly assigned to either the QCA-guided group, where PCI is performed on lesions with at least 50% diameter stenosis, or the FFR-guided group, where PCI targets lesions with FFR values of 0.80 or less. Imaging guidance during PCI is optional but left to the operators discretion, while routine high-pressure post-dilation is recommended. The study involves an initial procedure with possible staged procedures as needed. Participants will be followed clinically at 1, 6, and 12 months, and then up to 5 years after the initial procedure. Assessments include tracking death, myocardial infarction, unplanned repeat revascularization, bleeding, rehospitalization, and self-rated health. The study aims to collect data on these outcomes to compare the two revascularization strategies in terms of safety, efficacy, and cost-effectiveness over both short- and long-term periods.

Age: 19Years +All GendersPhase Not Applicable
17 locations
A

Actively Recruiting

Researchers are evaluating the use of an artificial intelligence-driven angiography-based fractional flow reserve MPFFR compared with invasive fractional flow reserve FFR to guide percutaneous coronary intervention PCI in patients with coronary artery disease. This multi-center, randomized controlled trial aims to determine if MPFFR-guided PCI is not inferior to invasive FFR-guided PCI in terms of clinical outcomes. The study addresses limitations of current FFR methods, such as the need for pressure wires and drug-induced hyperemia, by testing a faster, automated AI-based alternative. Participants will be randomly assigned to one of two groups the MPFFR-guided PCI group or the invasive FFR-guided PCI group. In the MPFFR group, AI software analyzes angiographic images to measure blood flow reserve without manual segmentation, with PCI recommended for lesions showing MPFFR values of 0.80 or less. In the invasive FFR group, a pressure wire and drugs are used to measure FFR, with PCI recommended for lesions with FFR values of 0.80 or less. Decisions to perform PCI are made by the treating doctors, and reasons for deferral are recorded. During the study, participants will undergo diagnostic coronary angiography followed by the assigned FFR measurement method. Researchers will monitor major adverse cardiac events one year after the last patient enrolls, along with other outcomes such as death, heart attacks, revascularization procedures, and procedure-related measures. The trial includes detailed follow-up to assess safety and effectiveness, with data collected on procedure times, contrast use, and device performance throughout the study period.

Age: 19Years +All GendersPhase Not Applicable
23 locations
P

Actively Recruiting

Researchers are evaluating the drug CMG190303 for treating adults with Type 2 Diabetes and Dyslipidemia. This phase III trial aims to compare how CMG190303 affects blood sugar control measured by HbA1c and cholesterol levels measured by LDL-C over 24 weeks, compared to two other treatments Rosuvastatin and Dapagliflozin. The study also monitors the safety of CMG190303 throughout the treatment period. Participants are randomly assigned to one of three groups those receiving CMG190303 a combination of Dapagliflozin and Rosuvastatin with doses increasing over 24 weeks, a group receiving Dapagliflozin with a Rosuvastatin placebo, or a group receiving Rosuvastatin with a Dapagliflozin placebo. The dosing schedule adjusts every 8 weeks with increasing amounts for both drugs in the CMG190303 group, while the placebo groups maintain consistent dosing. The trial is double-blinded, meaning neither participants nor researchers know which treatment is given. During the study, participants will have regular assessments to measure their HbA1c and LDL-C levels at various points up to 24 weeks. Additional blood tests will monitor fasting plasma glucose and other lipid parameters at 8, 16, and 24 weeks. Medication adherence is tracked, and safety monitoring is ongoing. The total participation duration is 24 weeks of treatment, during which researchers collect data to understand the drugs effects and safety in adults with these conditions.

Age: 19Years - 80YearsAll GendersPhase 3
24 locations
A

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the Synergy XD stent and Synergy Megatron122 Stent compared to other drug-eluting stents in patients with coronary artery disease. This study is a non-randomized, prospective, open-label registry designed to observe how these stents perform in real-world daily medical practice. The study aims to provide important information about outcomes such as death, heart attack, and the need for further vessel treatment. The study involves patients who receive percutaneous coronary intervention using either the Synergy XD stent or the Synergy Megatron122 stent. These devices are compared against other drug-eluting stents used in similar patients. Participants are followed over time with no random assignment to groups, allowing researchers to assess outcomes based on routine clinical care. Participants will be monitored through scheduled clinical follow-ups, with researchers tracking events including death, non-fatal myocardial infarction, and target vessel revascularization over one year. Additional outcomes such as cardiac death, stroke, stent thrombosis, and procedural success are assessed up to five years after treatment. The study collects data on patient safety and effectiveness of these stents during routine use, providing valuable long-term information on their clinical performance.

Age: 19Years +All Genders
23 locations
C

Actively Recruiting

Researchers are evaluating whether adding an Implantable Cardioverter Defibrillator ICD to optimal medical therapy reduces the overall death rate in patients with variant angina who have survived sudden cardiac arrest. This trial focuses on patients diagnosed with variant angina characterized by coronary spasms and who have experienced aborted sudden cardiac death. The study is a phase 4, randomized trial comparing ICD implantation plus medical therapy versus medical therapy alone. Participants are assigned to either receive an ICD implanted along with optimal medical therapy or continue with optimal medical therapy alone. The trial monitors participants for five years, tracking the occurrence of deaths and other cardiac-related events. Assessments include event rates of cardiac death, arrhythmia-related death, cardiac arrest, ventricular tachyarrhythmia recurrence, hospitalizations, ICD therapies, device complications, and strokes. Throughout the study, participants undergo regular monitoring over five years until the last participants final visit. Researchers collect data on survival and cardiac events to determine the effectiveness of ICD implantation alongside medical therapy. The total duration of participation is up to five years, with ongoing safety and event monitoring to capture detailed outcome information.

Age: 18Years +All GendersPhase 4
26 locations
O

Actively Recruiting

Researchers are studying patients with acute coronary syndrome ACS who have undergone percutaneous coronary intervention PCI to evaluate the effects of a treatment combining ticagrelor P2Y12 inhibitor monotherapy with low-dose colchicine. This study aims to determine how often serious cardiovascular events and stent thrombosis occur within 12 months after PCI when aspirin is discontinued and replaced by colchicine alongside ticagrelor. The research will also compare this approach to different durations of dual antiplatelet therapy from previous studies to assess its effectiveness and safety. Participants will take low-dose colchicine 0.6 mg once daily with ticagrelor maintenance therapy 90 mg twice daily after PCI, stopping aspirin the day after the procedure. One month following PCI, a high-sensitivity C-reactive protein hs-CRP test will be conducted colchicine will be stopped if hs-CRP is below 2 mgL or continued for 12 months if it is 2 mgL or higher. Patients will have scheduled clinic visits at 1, 3, 6, 9, and 12 months post-PCI for follow-up. During the study, participants will undergo regular check-ups including hs-CRP testing and monitoring for cardiovascular events, stent thrombosis, bleeding, inflammation, platelet activity, and drug reactions to colchicine. Researchers will track these outcomes at multiple time points up to 12 months to assess the treatments clinical effects and safety. The total participation period spans one year after the PCI intervention.

Age: 20Years - 90YearsAll GendersPhase 4
9 locations
C

Actively Recruiting

Researchers are comparing the effects of optical coherence tomography OCT-guided versus angiography-guided percutaneous coronary intervention PCI in patients who have suffered an acute myocardial infarction AMI. The study aims to determine if using OCT imaging during PCI can improve clinical outcomes by better guiding stent placement and optimization compared to traditional angiography alone. This trial addresses limitations of angiography and builds on previous research that has not conclusively shown long-term benefits of OCT guidance in AMI treatment. Participants will be randomly assigned to one of two groups one receiving standard PCI guided by angiography and the other receiving PCI guided by OCT imaging. In the OCT group, OCT imaging is used before, during, and after stent placement to optimize treatment, with specific criteria for stent expansion, apposition, and edge dissection. The angiography group will have PCI performed using standard visual assessments and stent optimization based on angiographic findings. Both groups undergo PCI procedures aimed at reopening blocked coronary arteries causing the heart attack. During the study, participants will be monitored for up to two years following their PCI procedure to assess clinical outcomes such as target vessel failure and other cardiac events. Researchers will collect data on death rates, myocardial infarctions, revascularization needs, stent thrombosis, and procedural details like fluoroscopy time and contrast use. Safety measures including monitoring for kidney injury related to contrast dye will also be included. This long-term follow-up will help determine the impact of OCT-guided PCI compared to angiography-guided PCI in patients with AMI.

Age: 19Years +All GendersPhase Not Applicable
18 locations
C

Actively Recruiting

Researchers are evaluating the best low-density lipoprotein LDL cholesterol targets for adults who have had a small vessel occlusion SVO stroke, a subtype of ischemic stroke. This trial addresses the lack of specific guidelines for LDL cholesterol levels tailored to different types of stroke, focusing on secondary prevention to reduce the risk of future cardiovascular events in patients with SVO stroke. The study is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial led by Seoul National University Hospital. Participants will be randomly assigned to one of two groups aiming for different LDL cholesterol targets an intensive group targeting LDL cholesterol below 70 mgdL and a standard group targeting LDL cholesterol between 90 and 110 mgdL. Both groups will receive lipid-lowering medications including statins andor ezetimibe, and PCSK9 inhibitors may be used if LDL targets are not reached with initial therapies. The trial plans to enroll 4,016 adults with confirmed SVO stroke within 180 days before randomization. During the study, participants will be monitored for major adverse cardiovascular events such as cardiovascular death, stroke, and acute coronary syndrome over a follow-up period of at least four years. Researchers will assess various outcomes including any stroke, ischemic stroke or transient ischemic attack, myocardial infarction, and hemorrhagic stroke. Participants will undergo regular evaluations to measure LDL cholesterol levels and cardiovascular health, with safety and adherence closely monitored throughout the trial duration.

Age: 19Years +All GendersPhase Not Applicable
46 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are investigating the safety of MenQuadfi, a meningococcal vaccine for groups A, C, Y, and W conjugated with tetanus toxoid, when given to people aged 6 weeks to 55 years in real-world healthcare settings. The study focuses on monitoring adverse drug reactions, including those not fully recognized or unexpected in usual clinical practice. Participants receive MenQuadfi as part of routine healthcare vaccination on the day they join the study. This observational study does not administer treatments but observes the vaccines use according to approved local guidelines. Different age groups have varying monitoring periods after vaccination, from about 44 days to 13 months. During the study, participants will be observed for injection site and systemic reactions up to 7 days post-vaccination, any non-serious adverse events or drug reactions up to 30 days, and serious or special interest adverse events throughout the follow-up period. The study includes infants and adults, with safety monitored through clinical observation and data collection. Participation duration varies by age group, with follow-up extending up to 13 months for the youngest infants.

Age: 6Weeks - 55YearsAll Genders
9 locations

1-10 of 15

1